Clinical trials
Phase 1 Retinoblastoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
25 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2011 | 3 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Terminated | 4 |
| Active, not recruiting | 2 |
| Recruiting | 2 |
| Unknown status | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Children's Oncology Group | 2 |
| Emory University | 2 |
| Eye & ENT Hospital of Fudan University | 2 |
| Masonic Cancer Center, University of Minnesota | 2 |
| Seattle Children's Hospital | 2 |
| Washington University School of Medicine | 2 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| Hospital JP Garrahan | 1 |
| Laboratorio Elea Phoenix S.A. | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Retinoblastoma | 25 |
| Neuroblastoma | 13 |
| Wilms Tumor | 12 |
| Medulloblastoma | 10 |
| Astrocytoma | 8 |
| Osteosarcoma | 8 |
| Sarcoma | 8 |
| Sarcoma, Ewing | 8 |
| Rhabdomyosarcoma | 7 |
| Hepatoblastoma | 6 |
Trials
Showing 1 to 25 of 25. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.